Solitaire-Iv: Results Of A Phase 3 Iv To Oral Trial In Adults With Community-Acquired Bacterial Pneumonia Comparing Solithromycin To Moxifloxacin

被引：0
|
作者：
File, T. M., Jr. [1 ]
Rewerska, B. [2 ]
Tanaseanu, C. M. [3 ]
Mihailovic-Vucinic, V. [4 ]
Gonong, J. R. [5 ]
Jamieson, B. D. [6 ]
Taylor, D. [6 ]
Sheets, A. [6 ]
Keedy, K. [6 ]
Oldach, D. W. [6 ]
Fernandes, P. [6 ]
机构：
[1] Summa Hlth Syst, Akron, OH USA
[2] Diamond Clin, Krakow, Poland
[3] St Pantelimon Emergency Clin Hosp, Bucharest, Romania
[4] Clin Ctr Serbia, Belgrade, Serbia
[5] Lung Ctr Philippines, Manila, Philippines
[6] Cempra Inc, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2116
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
    Horcajada, Juan P.
    Salata, Robert A.
    Alvarez-Sala, Rodolfo
    Nitu, Floarea Mimi
    Lawrence, Laura
    Quintas, Megan
    Cheng, Chun-Yen
    Cammarata, Sue
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (01):
  • [12] Results from a Phase 3 trial in Moderate to Moderately Severe Community Acquired Bacterial Pneumonia (CABP) Treated As Outpatients With a New Oral Macrolide, Solithromycin
    Oldach, David
    Barrera, Carlos
    Rowe, Brian
    Nitu, Floarea Mimi
    Mykietiuk, Analia
    Metev, Hristo
    Laabs, Jessica
    Mitha, Ismail
    Tanaseanu, Cristina Mihaela
    Molina, Joseph McDermott
    Antonovsky, Yuri
    Van Rensburg, Dirkie Johanna
    Flores, Jose
    Sokolowska, Barbara
    Doreski, Alexis
    Das, Anita
    Clark, Kay
    Jamieson, Brian
    Sheets, Amanda
    Keedy, Kara
    Fernandes, Prabhavathi
    CHEST, 2015, 148 (04)
  • [13] Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
    Alexander, Elizabeth
    Goldberg, Lisa
    Das, Anita F.
    Moran, Gregory J.
    Sandrock, Christian
    Gasink, Leanne B.
    Spera, Patricia
    Sweeney, Carolyn
    Paukner, Susanne
    Wicha, Wolfgang W.
    Gelone, Steven P.
    Schranz, Jennifer
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (17): : 1661 - 1671
  • [14] Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial
    McCurdy, Sandra
    Nenninger, Ashley
    Sheets, Amanda
    Keedy, Kara
    Lawrence, Laura
    Quintas, Megan
    Cammarata, Sue
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 97 : 374 - 379
  • [15] Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia
    Tanaseannu, Cristina
    Bergallo, Carlos
    Teglia, Osvaldo
    Jasovich, Abel
    Oliva, Maria Eugenia
    Dukart, Gary
    Dartois, Nathalie
    Cooper, C. Angel
    Gandjini, Hassan
    Mallick, Rajiv
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 61 (03) : 329 - 338
  • [16] IV cefuroxime plus oral clarithromycin or IV erythromycin for the treatment of community-acquired pneumonia in hospitalised patients - A pilot study
    Gotfried, MH
    Killian, AD
    Servi, RJ
    Danziger, LH
    Rodvold, KA
    CLINICAL DRUG INVESTIGATION, 1997, 14 (01) : 23 - 34
  • [17] IV Cefuroxime Plus Oral Clarithromycin or IV Erythromycin for the Treatment of Community-Acquired Pneumonia in Hospitalised PatientsA Pilot Study
    Mark H. Gotfried
    Aaron D. Killian
    Ronald J. Servi
    Larry H. Danziger
    Keith A. Rodvold
    Clinical Drug Investigation, 1997, 14 : 23 - 34
  • [18] Nabriva Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-acquired Bacterial Pneumonia
    Kaye, Donald
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (04) : I - II
  • [19] IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: Focus on gatifloxacin
    Lorenzo Pelly
    Advances in Therapy, 2002, 19 : 229 - 242
  • [20] IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: Focus on gatifloxacin
    Pelly, L
    ADVANCES IN THERAPY, 2002, 19 (05) : 229 - 242
12345